15.96 USD
▲+0.02+0.06%
盘后 15.94 -0.06%
2026-08-03
市值
$84.56M
市盈率
—
EPS
-1.38
股息率
—
52 周区间
3.20 – 17.57
成交量
44.90K
Beta
-0.89
目标价
—
52W 低 3.2052W 高 17.57
价格走势
公司简介
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to ...